Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on June 24, 2022. The registrant is incorporated in California and lists its common stock on The Nasdaq Stock Market LLC. The report addresses a specific corporate governance event rather than periodic financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding personnel changes and does not contain financial statements or operational metrics.
Material Changes
The primary material change reported is the departure of a senior executive:
- Resignation: Li Yu resigned as Vice President, Controller, and Principal Accounting Officer effective June 24, 2022.
- Reason: Ms. Yu resigned to pursue other opportunities.
- Disagreements: The Company confirmed there were no disagreements between Ms. Yu and the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements disclaiming any obligation to update future projections. It directs investors to the "Risk Factors" section of the Company's Annual Report on Form 10-K for factors that could cause actual results to differ from anticipated results. No specific guidance, outlook, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the appointment of a new Principal Accounting Officer or Controller to replace Li Yu.
- Review the Company's most recent Form 10-K for detailed risk factors and financial health.
- Monitor subsequent filings for any updates regarding the transition of accounting responsibilities.